孟鲁司特预防过敏性紫癜肾损害的临床效果观察

目的：探讨孟鲁司特防治过敏性紫癜肾损害的临床有效性和安全性。方法：采用随机对照方法，将200例过敏性紫癜患儿分为实验组（100例）和对照组（100例），两组患儿均给予常规治疗，实验组采用孟鲁司特进行治疗，对照组采用低分子肝素钙进行治疗，观察两组临床治疗效果及不同时间段微量白蛋白、尿β2微球蛋白变化。结果：实验组有效率为91．00％，明显高于对照组的81．OO％（X2=4．15，P〈0．05）。实验组儿童皮疹消失时间、腹痛和关节疼痛缓解时间以及总病程均明显短于对照组（P〈0．01）。治疗后实验组尿微量白蛋白、尿8。微球蛋白水平明显低于对照组（P〈0．01）。结论：孟鲁司特预防过敏性紫癜肾损害方法简单，安全可靠，值得临床推广应用。

Clinical observation of montelukast in prevention of Henoch-Schonlein purpura with renal impairment

ABSTRACT AIM. To observe the clinical effi- cacy and safety of montelukast in prevention of Henoch-Schonlein purpura with renal impair- ment. METHODS： Using a randomized con- trolled method, 200 cases of Henoch-Schonlein syndrome were randomly divided into the experi- mental group （n = 100） and control group （n = 100） ,two groups were given conventional treat- ment, the experimental group was based on com- bined with montelukast and the control group was based on combined with low molecular hepa- rin sodium. The clinical treatment result, the changes of urine albumin and β2 mieroglobulin levels in different time periods were observed. RESULTS： Efficacy of the experimental group was 91. 00% while the control group was81.00% （X2 =4.15, P〈0.05） . Compared with the control group,the children disappearing time rash, abdominal pain and joint pain remission time and the total duration in the experimental group were significantly shorter （P〈0.01）. Af- ter treatment, the levels of urinary albumin and urinary β2 microglobulin in experimental group were significantly lower than those in the control group （P〈0. 01）. CONCLUSION： The preven- tive effect of montelukast on henoch-schonlein purpura with renal involvement method is sim- ple, safe, so it deserves preference in clinic.